Canaccord Genuity Starts Zalicus (ZLCS) at Buy; Synavive: Safer Steroid with Significant Potential in RA
Tweet
Share
E-mailGet Alerts ZLCS Hot Sheet
Price: $1.18 --0%
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity initiates coverage on Zalicus (NASDAQ: ZLCS) with a Buy. PT $3.00.
Canaccord analyst, Ritu Baral, said, "Synavive is Zalicus’ Phase 2 drug for RA. We think Synavive has significant market potential in various conditions where low-dose chronic steroids are used. We think the drug may be equally efficacious but significantly safer than steroids and more cost-effective than biologics. We also think Zalicus has a very promising platform of ion channel modulators for chronic pain, including Phase 1b-ready Z160, a novel calcium channel blocker."
For more ratings news on Zalicus click here and for the rating history of Zalicus click here.
Shares of Zalicus closed at $1.32 yesterday.
Canaccord analyst, Ritu Baral, said, "Synavive is Zalicus’ Phase 2 drug for RA. We think Synavive has significant market potential in various conditions where low-dose chronic steroids are used. We think the drug may be equally efficacious but significantly safer than steroids and more cost-effective than biologics. We also think Zalicus has a very promising platform of ion channel modulators for chronic pain, including Phase 1b-ready Z160, a novel calcium channel blocker."
For more ratings news on Zalicus click here and for the rating history of Zalicus click here.
Shares of Zalicus closed at $1.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- RBC Capital Starts Krystal Biotech (KRYS) at Outperform
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
